Abstract
The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein degradation and regulates various cellular events including cell cycle progression, transcription, DNA repair, signal transduction, and immune response. Ubiquitin, a highly conserved small protein in eukaryotes, attaches to a target protein prior to degradation. The polyubiquitin chain tagged to the target protein is recognized by the 26S proteasome, a high-molecular-mass protease subunit complex, and the protein portion is degraded by the 26S proteasome. The potential of specific proteasome inhibitors, which act as anti-cancer agents, is now under intensive investigation, and bortezomib (PS-341), a proteasome inhibitor, has been recently approved by FDA for multiple myeloma treatment. Since ubiquitination of proteins requires the sequential action of three enzymes, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3), and polyubiquitination is a prerequisite for proteasome-mediated protein degradation, inhibitors of E1, E2, and E3 are reasonably thought to be drug candidates for treatment of diseases related to ubiquitination. Recently, various compounds inhibiting the ubiquitin-proteasome pathway have been isolated from natural resources. We also succeeded in isolating inhibitors against the proteasome and E1 enzyme from marine natural resources. In this review, we summarize the structures and biological activities of natural products that inhibit the ubiquitinproteasome proteolytic pathway.
Keywords: Natural product, ubiquitin-proteasome proteolytic pathway, ubiquitin, ubiquitination, ubiquitin-activating enzyme, ubiquitin-conjugating enzyme, ubiquitin-protein ligase, proteasome
Current Medicinal Chemistry
Title: Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development
Volume: 13 Issue: 7
Author(s): Sachiko Tsukamoto and Hideyoshi Yokosawa
Affiliation:
Keywords: Natural product, ubiquitin-proteasome proteolytic pathway, ubiquitin, ubiquitination, ubiquitin-activating enzyme, ubiquitin-conjugating enzyme, ubiquitin-protein ligase, proteasome
Abstract: The ubiquitin-proteasome proteolytic pathway plays a major role in selective protein degradation and regulates various cellular events including cell cycle progression, transcription, DNA repair, signal transduction, and immune response. Ubiquitin, a highly conserved small protein in eukaryotes, attaches to a target protein prior to degradation. The polyubiquitin chain tagged to the target protein is recognized by the 26S proteasome, a high-molecular-mass protease subunit complex, and the protein portion is degraded by the 26S proteasome. The potential of specific proteasome inhibitors, which act as anti-cancer agents, is now under intensive investigation, and bortezomib (PS-341), a proteasome inhibitor, has been recently approved by FDA for multiple myeloma treatment. Since ubiquitination of proteins requires the sequential action of three enzymes, ubiquitin-activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin-protein ligase (E3), and polyubiquitination is a prerequisite for proteasome-mediated protein degradation, inhibitors of E1, E2, and E3 are reasonably thought to be drug candidates for treatment of diseases related to ubiquitination. Recently, various compounds inhibiting the ubiquitin-proteasome pathway have been isolated from natural resources. We also succeeded in isolating inhibitors against the proteasome and E1 enzyme from marine natural resources. In this review, we summarize the structures and biological activities of natural products that inhibit the ubiquitinproteasome proteolytic pathway.
Export Options
About this article
Cite this article as:
Tsukamoto Sachiko and Yokosawa Hideyoshi, Natural Products Inhibiting the Ubiquitin-Proteasome Proteolytic Pathway, A Target for Drug Development, Current Medicinal Chemistry 2006; 13 (7) . https://dx.doi.org/10.2174/092986706776055571
DOI https://dx.doi.org/10.2174/092986706776055571 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Herpesvirus Encoded dUTPase as a Potential Chemotherapeutic Target
Current Protein & Peptide Science Azidothymidine is Effective Against Human Multiple Myeloma: A New Use for an Old Drug?
Anti-Cancer Agents in Medicinal Chemistry Advances in the Development of Anticancer HSP-based Vaccines
Current Medicinal Chemistry Phytochemicals to Prevent Inflammation and Allergy
Recent Patents on Inflammation & Allergy Drug Discovery The Molecular Basis of Herpesviruses as Oncolytic Agents
Current Pharmaceutical Biotechnology Signal Transduction in HIV Protein-Treated Astrocytes
Current Signal Transduction Therapy Oxidative stress and myocarditis
Current Pharmaceutical Design Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Visualization of Nonspecific Antitumor Effectiveness and Vascular Effects of Gene Electro-Transfer to Tumors
Current Gene Therapy The Controlled Release of Drugs and Bioactive Compounds from Mesoporous Silica Nanoparticles
Current Drug Delivery Novel Insights Into c-Src
Current Pharmaceutical Design DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science A Role for the Inflammatory Mediators Cox-2 and Metalloproteinases in Cancer Stemness
Anti-Cancer Agents in Medicinal Chemistry Biomaterials and Scaffolds in Bone and Musculoskeletal Engineering
Current Stem Cell Research & Therapy Clinical Trials with Oncolytic Adenovirus in China
Current Cancer Drug Targets Molecular Imaging of Matrix Metalloproteinases In Vivo Using Small Molecule Inhibitors for SPECT and PET
Current Medicinal Chemistry Dynamics of Virus-Host Interplay in HIV-1 Replication
Current HIV Research Novel Rational Drug Design Strategies with Potential to Revolutionize Malaria Chemotherapy
Current Medicinal Chemistry A Review on Exploring Better Safety Prospects in Managing Cancer using Liposomal Combinations of Food Bioactive Compounds and Anticancer Drugs: Combisomes
Current Drug Delivery Radiopharmaceutical Tracking of Particles Injected into Tumors: A Model to Study Clearance Kinetics
Current Drug Delivery